Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report)’s share price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.26 and traded as high as $3.1848. Cortexyme shares last traded at $2.98, with a volume of 701,706 shares.
Cortexyme Stock Down 3.2%
The company has a 50-day moving average of $3.27 and a 200-day moving average of $2.26. The company has a market cap of $89.85 million, a PE ratio of -1.00 and a beta of 1.40.
About Cortexyme
Cortexyme, Inc is a clinical-stage biotechnology company focused on the development of treatments for Alzheimer’s disease and other chronic conditions associated with bacterial proteases. The company’s research centers on targeting virulence factors produced by the oral pathogen Porphyromonas gingivalis, an organism increasingly implicated in neurodegeneration. By inhibiting the activity of gingipains—proteolytic enzymes secreted by P. gingivalis—Cortexyme aims to reduce inflammation and tissue damage in the brain and other organs.
The company’s lead product candidate, atuzaginstat (COR388), is a small-molecule inhibitor designed to cross the blood–brain barrier and neutralize gingipain activity.
Featured Articles
- Five stocks we like better than Cortexyme
- America’s Next Power Move Starts Underground
- Your Signature Is Missing – Act Before It’s Too Late
- URGENT: Trump Just Triggered AI’s Biggest Disruption Yet
- NEW LAW: Congress Approves Setup For Digital Dollar?
- The biggest scam in the history of gold markets is unwinding
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
